Cerapedics, a 2012 Colorado Companies to Watch (COCTW) winner, is a privately held medical device company focused on developing and commercializing novel osteobiologic products based on its proprietary anorganic bone mineral (ABM) and synthetic small peptide (P-15™) technology platform. previously announced the company submitted to the FDA the first several modules of its premarket approval application (PMA) for its i-FACTOR bone graft.Ībout Cerapedics, Inc. This novel mechanism of action enhances the bodys natural bone healing process resulting in safe, predictable bone formation. i-FACTOR bone graft is currently being evaluated in the United States (FDA) as part of an Investigational Device Exemption (IDE) Clinical Study in the cervical spine. i-FACTOR Putty combines a unique anorganic bone mineral (ABM) and small peptide (P-15) that acts as an attachment factor for specific integrins on osteogenic cells. i-FACTOR Biologic Bone Graft novel mechanism of action enhances the bodys natural bone healing process, resulting in safe, predictable bone formation. Continuarea navigrii pe site se consider acceptare a politicii de utilizare cookies.

Pentru a v asigura cea mai bun experien, iFactor.ai foloseste cookies. All of our physicians are board certified or board eligible. iFactor your digital tool for intermediating all operations, ensuring a fast, smooth, secure process. Currently, i-FACTOR bone graft is commercially available in both a Putty and Flex (flexible strip) form in more than 20 countries outside the United States. With educational backgrounds from some of the most prestigious medical schools in the nation, Peachtree Orthopedics physicians are widely known for their diverse expertise. Cerapedics’ i-FACTOR bone graft received CE Mark in late 2008 and has been utilized clinically in over 10,000 spine, trauma and orthopedic surgeries worldwide. Steve McAdoo, Vice President of Marketing at Cerapedics, stated, “This is a significant achievement and milestone for the company and confirms that i-FACTOR bone graft can provide a viable treatment option to both surgeons and patients looking for an alternative to either autograft harvesting or expensive growth factor technologies.” i-FACTOR Peptide Enhanced Bone Graft incorporates Cerapedics’ proprietary anorganic bone mineral (ABM) and synthetic small peptide (P-15™) technologies for use in a wide variety of spine, trauma and orthopedic surgical procedures. (Westminster, CO), a medical device company pioneering the use of peptide enhanced bone grafting materials in spine, trauma and orthopedic surgery, is pleased to announce it has surpassed another significant milestone with more than 10,000 patients treated with i-FACTOR™ Peptide Enhanced Bone Graft since the product became available outside the United States in late 2008. VIA Graft allografts feature a proprietary optimized bone microparticulate size range of 100-300m. WESTMINSTER, Colo.–(BUSINESS WIRE)–Mar 4, 2013–Cerapedics, Inc. oral and maxillofacial, and orthopedic oncology.

Ifactor ortho